Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

185 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-01

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations and their difficulties. Secondly, the ELECT-RO study demonstrated the validity of the measurement scale, meaning that QoL-HHT does indeed measure patients' QoL and is therefore a reference tool.

QoL-HHT gives investigators a good understanding of the different aspects of patients' QoL (physical limitations, concerns about bleeding, concerns about the evolution of the disease, social relationships, relationships with healthcare professionals and the experience of the disease), whether they are affected or not, at an individual level.

Today, investigators believe it is important to take a more global (population-based) view of the aspects of quality of life affected by HHT. While studies have shown the importance of the role of epistaxis (frequency, duration, intensity, experience) in QoL, what about other symptoms and clinical signs?

The DISQUO study, which the researchers plan to start today, is a follow-up to ELECT-RO. It should enable the researchers to gain a better understanding of the QoL of people with HHT and the impact of each symptom of HHT on patients' QoL.

The DISQUO study will therefore allow the investigators to gain a better understanding of the impact of HHT symptoms on the different areas of patients' QoL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypoplastic Left Heart Syndrome: Subendocardial Viability After Norwood Palliation

NCT05709275

Hypoplastic Left Heart Syndrome

TERMINATED

Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia

NCT02690246

Hereditary Haemorrhagic Telangiectasia (HHT)

COMPLETED

TEGSEDI Pregnancy Surveillance Program

NCT04270058

Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy Pregnancy

NOT_YET_RECRUITING

Development of an Assessment Tool for Health-related Quality of Life in Children and Adolescents With Pompe Disease

NCT04724213

Pompe Disease

COMPLETED NA

Institutional Registry of Rare Diseases

NCT06573723

Rare Diseases Amyloidosis Sarcoidosis +23 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Hemorrhagic Telangiectasia (HHT)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HHT patients

completion of the QoL-HHT questionnaire during a consultation at the reference centre

completion of the QOL-HHT questionnaire

Intervention Type OTHER

filling in the QOL-HHT questionnaire when they come for consultation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

completion of the QOL-HHT questionnaire

filling in the QOL-HHT questionnaire when they come for consultation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with clinically (presence of at least 3 Curaçao criteria) and/or molecularly confirmed HHT disease
* Patient of legal age (over 18 years old)
* Patient who has received the information and has not objected to taking part in the study